How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Recursion Pharmaceuticals reported mixed Q2 2026 results, highlighting significant clinical advancements and a notable collaboration with Genentech. Despite a revenue decline to $7.67 million, the ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

Infinity (Infinity Artificial Intelligence Institute), an early-stage AI infrastructure research company building the software layer that makes any AI chip inference-ready, today announced a new case ...